London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Adviser Biographies
Professor Cherry Wainwright
Cherry graduated from the University of Aberdeen with a BSc (Hons) in Pharmacology and subsequently the University of Strathclyde with a PhD in Cardiovascular Pharmacology. Her research career spans more than 42 years, with over 20 years spent at Strathclyde University before moving to Robert Gordon University in Aberdeen where she spent 8 years as the Director of the multi-disciplinary Institute for Health & Wellbeing Research and was the lead in Cardiometabolic Health Research and Co-Director of the Centre for Natural Products in Health.
Throughout her career, Cherry has worked continuously in collaboration with industry conducting research on the identification of novel therapeutic targets of cardiovascular diseases. For the last 20 years her focus has been on the influence of endocannabinoids and phytocannabinoids on various cardiovascular disorders (ischaemia/reperfusion, cardiac fibrosis), vascular (atherosclerosis, restenosis) injury and cardiac energy regulation.
Cherry has published around 100 full original articles and invited reviews and holds 3 patents. She is a Fellow of the British Pharmacological Society, for which she is currently President Elect.
Dr. Katie Sloper, PhD
Katie graduated from the University of New England with a BSc in Biochemistry, Microbiology and Nutrition, receiving several university Prizes for Excellence. Katie was then the recipient of the University Medal at the Australian National University (ANU) for her Honours thesis on DNA damage repair pathways. Katie subsequently completed her PhD at ANU with a focus on cancer research, before completing postdoctoral fellowships in both Australia and the USA.
In addition to her medical research Katie has over 15 years working in healthcare across both public and private sectors, including as a Senior Policy Advisor to the Queensland Minister for Health and a Member of the Pharmacy Board of Australia. Katie's medical research has recently focussed on understanding the therapeutic profile of cannabis-based medicines and investigating innovative approaches to cancer treatment.
Ananda Developments Plc ('Ananda'), a company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions, is pleased to announce the appointment of Professor Cherry Wainwright and Dr. Katie Sloper, PhD as scientific advisers to assist the Company in developing its in-house capabilities and pipeline of clinical trials.
Professor Cherry Wainwright is a pharmacological research expert with over 42 years of experience and is the President Elect of the British Pharmacological Society ('BPS'), a charity with a mission to promote and advance the whole spectrum of pharmacology (the scientific study of the effects of drugs and chemicals on living organisms). The BPS leads the way in the research and application of pharmacology around the world and has over 4,000 members from more than 60 countries worldwide. Cherry will advise the Company on its drug development activities, areas of potential unmet need that could benefit from Ananda's medicines, and clinical trial activities including protocol development.
Dr. Katie Sloper, PhD is a medical research expert with a particular focus on the therapeutic profile of cannabis-based medicines and innovative approaches to cancer treatment. Katie's work with Ananda will focus on developing the Company's scientific understanding of cannabidiol and its mechanisms of action, with a particular focus on chronic pain and inflammation. Katie will help the Company to continually refine its scientific approach and identify potential new areas for clinical investigation.
Ananda's Chairman, Charles Morgan, commented "Having worked with Cherry and Katie for some time, I am delighted that they are joining Ananda as scientific advisers to support our objective of gaining approval for MRX's cannabis-based formulations to be used in the NHS. Strengthening our team with these highly regarded scientists will both enhance our scientific capabilities and help us to target our research and development efforts even more effectively. It is also a huge opportunity for Ananda to explore new areas of potential unmet need where our cannabinoid medicines could benefit patients”
Very interesting to see us move towards additional areas to do Rct work!! Its a watch this space for sure! And building a company here to me that will be worthy of a big pharma approach or two further down the line!
Https://twitter.com/ToniaAntoniazzi/status/1747575040655167821?t=paGXZeXycA7JczHScyxJ4Q&s=19
Https://twitter.com/AnandaPlc/status/1747590954243006934?t=eABlSZeVky3_WR8m2BYx6Q&s=19
Don't forget to breath,in through the nose out through the mouth or there is CBD simply as 123
Its not working 6060 we have had our fingers burnt and still smarting ,keep your bod thoughts in the board room
God we are so undervalued its un real...........
Centre of excellence with Nottingham Trent.
And completion of stabilisation program pending.
Edinburgh university rct's with Nhs Funding!.
Early callers of seed is best! Great call.
Using 3rd party funding to build internal value.
Unprecedented approaches in play..........
It's coming and if your making all the right moves your going to do very well indeed with any NHS adoption
All pointing in the same direction now.
Https://ukt.news/what-are-londons-most-influential-health-diagnostics-startups-in-2023/
Https://cannabizeu.com/nhs-joins-forces-with-ananda-for-mrx1-endometriosis-trial/
Https://cannabizeu.com/medical-cannabis-as-a-solution-for-chronic-neuropathic-pain/
To be part of this simply join The Hive on Telegram with over 3000 members it's a big following!
Https://cannabishealthnews.co.uk/2024/01/05/cannabis-in-europe-7-reasons-to-be-optimistic-for-2024/
Here is the response…which is what I expected to honest, but thought I’d chance my arm anyway… 😁
Hi Dave, thanks for your question and we’re glad to know you appreciate the Hub. All reporting on sales will be made formally in annual & interim financial statements. Whilst the market is still in its infancy (between 20,000 and 30,000 patients nationally) our core focus is on building trust with clinicians via the collection of strong & positive clinical data via our clinical trial pipeline. It is our opinion that the only path to significant and consistent sales is by treating our formulations like every other medicine and that means providing the NHS and MHRA with the evidence they need to add MRX oils to Public Health medicine formularies.
I'm struggling to insert answer to the question by cut and paste but if you join the Hub the you can see
DaveBurgin
07:57AM 21/12/2023
Hi - The hub looks great and another example of improving shareholder engagement.
A quick question… In July Ananda announced that both MRX1 and MRX2 Had been made available to 3 private pain clinics. Has there been any uptake of these by the clinics to prescribe to patients?
MRX's patent pending MRX1 cannabidiol oil formulation will be used as the Investigative Medicinal Product ("IMP") in the trial. MRX is supplying the MRX1 CBD formulation and matched placebo.
· MRX has been granted a licence over all arising (generated from the trial) Intellectual Property ("IP") for internal research and development purposes, as well as an option to licence the arising IP for all commercial purposes. MRX will maintain full ownership of all IP as relates to the IMP and Placebo.
Ananda's CEO, Melissa Sturgess commented: "The drug supply agreement provides the legal framework for the provision of MRX1, our patent pending cannabinoid medicine, to the CIPN randomised controlled trial. Importantly it also confirms that MRX retains full IP ownership of the medicine and provides Ananda with a pathway to utilise the IP from the trial for commercial purposes. This will be a crucial part of Ananda's value if the trial is successful and the medicine is able to be commercialised via the NHS."
To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:
· Investor Hub: investors.anandadevelopments.com
· Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
Hi DJ and thanks for your question.
It is an interesting point, though I don't think we would look to change names at this point. We would probably have to look at changing our ticker (ANA) as well and probably undergo a wider rebrand which may pull focus and resource from our main aim of executing on the two Phase II clinical trials we have agreed to date, expanding our trial pipeline and securing & building on our relationship with Nottingham Trent Uni on DJT. There is also every chance that a name change could cause more problems than it solves with regards to finding info on the Company as you're effectively starting again from 0.
If we ever do decide to change names though, I am sure